Cardiff Oncology, Inc. (CRDF) Misses Q1 EPS by 1c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q1 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $91.67 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Popular stocks with increasing option volume: SPCX MU INTC NFLX PLTR SOFI MSTR AMC IBM SMCI HOOD
• SpaceX short interest at 5-7% of float - S3 Partners